Pharma BD Deal Intelligence
Vertex paid CRISPR Therapeutics $100M upfront for non-exclusive rights to CRISPR/Cas9 technology to accelerate development of Vertex's hypoimmune (gene-edited) islet cell therapies for Type 1 diabetes; CRISPR is eligible for up to $230M in R&D milestones plus royalties on future products. The strategic goal is an off-the-shelf islet cell therapy that does not require chronic immunosuppression. Post-deal: Vertex's unedited islet program zimislecel (VX-880), which still requires immunosuppression, advanced to Phase 3 and posted positive 12-month ADA data in June 2025 (full-dose participants achieved insulin independence), with global regulatory submissions guided for 2026. A separate device-based immunosuppression-free route, VX-264 (encapsulated cells, no gene editing), missed its Phase 1/2 efficacy endpoint and was discontinued in March 2025 (~$400M asset impairment). The CRISPR-licensed gene-edited hypoimmune approach -- editing zimislecel-derived cells to cloak them from the immune system -- remains the active, preclinical path to an immunosuppression-free therapy, keeping the deal thesis intact.